Enzalutamide

51 trials 26 recruiting LOncology

Filter these 51 trials by condition, phase, country and more.

Open in Search →

51 Registered trials

26 Recruiting

24 Completed trials

32 Sponsors

25 Countries

Phase III

Phase II

Phase I/II

Phase III: 29 Phase II: 9 Phase I/II: 7 Phase IV: 4 Phase I (FiH): 2

Oversight events:

1 serious breach 27 temporary halts 1 urgent safety measure 7 unexpected events across 7 trials

View oversight register →

Indications tested

Prostate cancer metastatic 14 Prostate cancer 4 Hormone-refractory prostate cancer 2

Sponsors using this IMP

Novartis Pharma AG 8 Merck Sharp & Dohme LLC 6 Pfizer Inc. 5 AstraZeneca AB 2 Cancer Trials Ireland 2 European Organisation For Research And Treatment Of Cancer 2 Region Vaesterbotten 2 UZ Leuven 2 Amgen Inc. 1 Asociacion Instituto De Investigacion Sanitaria Biobizkaia 1 Astellas Pharma Global Development Inc. 1 Bayer AG 1

All trials — page 3

51 total

Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended

2023-507024-24-00 Phase III 3 countries Merck Sharp & Dohme LLC
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Phase III 11 countries Merck Sharp & Dohme LLC
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat… Ended

2024-514808-13-00 Phase III 3 countries Cancer Trials Ireland

Showing 49–51 of 51 trials

← All drugs A–Z